Human RUNX3 knockout A549 cell line
Be the first to review this product! Submit a review
|
(0 Publication)
RUNX3 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided.
View Alternative Names
AML 2, Acute myeloid leukemia 2 protein, Acute myeloid leukemia gene 2, CBF-alpha-3, CBFA 3, Core binding factor alpha 3 subunit, Core binding factor runt domain alpha subunit 3, Core-binding factor subunit alpha-3, Oncogene AML-2, PEA2-alpha C, PEBP2-alpha C, PEBP2aC, Pebp2a3, Polyomavirus enhancer-binding protein 2 alpha C subunit, RUNX3_HUMAN, Runt-related transcription factor 3, SL3-3 enhancer factor 1 alpha C subunit, SL3/AKV core-binding factor alpha C subunit, Transcription factor AML2, core-binding factor, runt domain alpha subunit 3
- NGS
Supplier Data
Next Generation Sequencing - Human RUNX3 knockout A549 cell line (AB288880)
110 total bp deletion after Asp 102 (Allele 1); 1 bp insertion after Gly 103, 8 bp deletion downstream of premature Stop codon.
Reactivity data
Product details
Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.
Recommended control: Human wild-type A549 cell line (ab288558). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Handling procedures
Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.
Subculture guidelines
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
- Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium
F-12K + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The function of RUNX3 involves the regulation of cell proliferation differentiation and apoptosis. RUNX3 often forms a complex with the core-binding factor beta (CBFβ) enhancing its stability and DNA-binding capability. This protein is essential in maintaining cellular homeostasis and influencing the immune response particularly through its role in T cell development.
Pathways
RUNX3 is heavily involved in the TGF-beta signaling pathway and the Wnt signaling pathway. It interacts with several proteins such as SMADs in the TGF-beta pathway to modulate gene expression that affects cell growth and survival. Interaction with beta-catenin in the Wnt signaling pathway further emphasizes its importance in regulating cell fate decisions.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 1 US: 1
Adherent/suspension
Adherent
Gender
Male
Target data
Complementary Products
![Western blot - Anti-RUNX3 antibody [2B3] (AB135248)](https://content.abcam.com/products/images/runx3-antibody-2b3-ab135248--western-blot-img137626.jpg)
Primary Antibodies
AB92336
Anti-RUNX1 / AML1 + RUNX3 + RUNX2 antibody [EPR3099]
BOND RX™ Validated|Recombinant|Advanced Validation|RabMAb
![Western blot - Anti-RUNX1 / AML1 + RUNX3 + RUNX2 antibody [EPR3099] (AB92336)](https://content.abcam.com/products/images/runx1-aml1-runx3-runx2-antibody-epr3099-ab92336--western-blot-img59181.jpg)
- 5
- 4
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GFP antibody [EPR14104] (AB183734)](https://content.abcam.com/products/images/gfp-antibody-epr14104-ab183734--immunohistochemistry-formalin-pfa-fixed-paraffin-embedded-sections-img118591.jpg)
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com